- BUZZ-QXO shares rise, boosted by preliminary Q3 results
- Stifel resumes coverage on Starbucks with a Buy rating and a target price of $115.
- EU taps industry to set standards for tokenized securities
- Wedbush lowers the target price for Cerebras Systems to $190.
- Advanced Medical Solutions Enters Preferred Partnership With NAMSA to Accelerate Product Development
- Uniti Group swings to Q3 net loss of $244.5 million
- ImmunityBio 3Q Research and Development Expense $71.5M >IBRX
- Azora Therapeutics Appoints Habtezion, Hastings and Soloway to Board
- ADENTRA 3Q Adjusted EBITDA $55.2M >ADEN.T
- ImmunityBio 3Q Loss/Shr 18c >IBRX
- ADENTRA 3Q Sales $618.7M >ADEN.T
- AbraSilver Intersects 75 Meters Grading 2.44 g/t Gold at Diablillos Project
- Revival Gold Acquires Property Interests at Mercur Gold Project in Utah
- ZILLOW GROUP, INC. <ZG.O>: KEYBANC CUTS TO SECTOR WEIGHT FROM OVERWEIGHT
- YeboYethu Expects Interim Net Asset Value per Share to Rise 30%-35%
- Nevada Sunrise Completes Ground Gravity Survey at Fivemile Gold Project
- Bicara Therapeutics Q3 2026 net loss widens 96% to $71.25 million
- Metals Creek Plans Exploration at Ontario Properties Using Private Placement Proceeds
- Lahontan Gold plans drilling to test historic waste rock at Santa Fe mine
- GRANITE REAL ESTATE INVESTMENT TRUST <GRT_u.TO>: RAYMOND JAMES RAISES TARGET PRICE TO C$103 FROM C$102
- Boston Pizza Fund 3Q Same-Restaurant Sales Rose 3.9% >BPF.UN.T
- Neurogene 3Q Loss/Shr $1.05 >NGNE
- Boston Pizza Fund Declares C$0.126 Monthly Distribution >BPF.UN.T
- Boston Pizza Fund 3Q Franchise Sales C$257.5M >BPF.UN.T
- Greenland Mines Raises Stake in AnorTech to 19.9%
- ImmunityBio Q3 net loss more than doubles to $184.57 million
- T-MOBILE <TMUS.O>: ARGUS RESEARCH CUTS TARGET PRICE TO $220 FROM $245
- CervoMed Q3 2026 net loss narrows 23% to $5.9 million
- Goodyear Names Roger Wood Interim CEO as Mark Stewart Steps Down
- GLOBALFOUNDRIES INC. <GFS.O>: ARGUS RESEARCH CUTS TARGET PRICE TO $70 FROM $90
- Neurogene Q3 net loss widens 39% to $29.02 million
- Uniti Group Sees 2026 Adjusted EBITDA $1.46B-$1.49B >UNIT
- CONSTELLATION SOFTWARE INC. <CSU.TO>: RAYMOND JAMES RAISES TARGET PRICE TO C$3,800.00 FROM C$3,500.00
- Rekor Systems Publishes Update to Financial Calendar
- Adentra Q3 2026 Net Income Jumps 57% to USD 15.9 Million
- PharmAla Biotech Signs Deal to Supply MDMA for Aalborg University Hospital PTSD Trial
- BRINKER INTERNATIONAL INC <EAT.N>: ARGUS RESEARCH CUTS TARGET PRICE TO $240 FROM $280
- Cognition Therapeutics to Attend Jefferies Global Healthcare Conference
- Turning Point Brands Q3 net income drops 81% to $3.93 million
- ADC Therapeutics Q3 net loss narrows 38% to $25.3 million
- Spanish Mountain Gold Expands Near-Surface Higher-Grade Mineralization at British Columbia Project
- ICE Plans December 2026 Launch of Wind Futures in European Energy Market Expansion
- FTI Consulting Announces Appointment of Moe Kelley and Brian Bagenstose to Board
- Zimmer Biomet to Present at Annual Jefferies Global Healthcare Conference
- Immuneering Appoints Grant Bogle to Bd of Directors
- Uniti Group Raises 2026 View To Rev $3.665B-$3.695B >UNIT
- CHARTWELL RETIREMENT RESIDENCES <CSH_u.TO>: RAYMOND JAMES RAISES TARGET PRICE TO C$25 FROM C$24
- BUZZ-Zura Bio shares plummet after mid-stage trial failure of skin disease drug
- Uniti Group 3Q Adjusted EBITDA $289.3M >UNIT
- CervoMed 2Q Research and Development Expenses About $3.7M >CRVO
- Braveheart Bio to Participate in Jefferies Global Healthcare Conference
- Netcapital Gets Nasdaq Extension Until Feb. 9 to File Overdue Reports
- BOYD GROUP SERVICES INC <BYD.TO>: RAYMOND JAMES CUTS TARGET PRICE TO C$240 FROM C$270
- ZIMMER BIOMET HOLDINGS, INC. <ZBH.N>: BARCLAYS RAISES TARGET PRICE TO $115 FROM $100
- AN2 Therapeutics 3Q Loss/Shr 17c >ANTX
- Uniti Group 3Q Rev $848.1M >UNIT
- Turning Point Brands 3Q EPS 19c >TPB
- Turning Point Brands 3Q Sales $151.1M >TPB
- Boston Pizza Fund 3Q Rev C$13.7M >BPF.UN.T
- Boston Pizza Fund 3Q Loss/Shr C$0.33 >BPF.UN.T
- Adcorp to acquire Alliance Workplace Solutions for A$ 4.3 million
- Via Transportation Publishes Q3 2026 Earnings Call Transcript
- CG ONCOLOGY, INC. <CGON.O>: WEDBUSH RAISES TARGET PRICE TO $84 FROM $80
- Heron Bd to Evaluate Various Strategic Transactions for Use of Transaction Proceeds, Including Acquiring or Investing in Further Businesses or Assets, Which May or May Not Be Pharmaceutical or Biotechnology Businesses or Assets >CRMD HRTX
- CEREBRAS SYSTEMS INC <CBRS.O>: WEDBUSH CUTS TARGET PRICE TO $190 FROM $290
- Heron to Retain Significant Federal, State Net Operating Loss Carryforwards (about $2.3B as of Sept 30) >CRMD HRTX
- GPI Wins €14 Million Contract for Trento Accounting System
- DRAFTKINGS INC. <DKNG.O>: NORTHLAND CAPITAL CUTS TARGET PRICE TO $20 FROM $28
- ALGONQUIN POWER & UTILITIES CORP. : RAYMOND JAMES CUTS TARGET PRICE TO $7 FROM $7.25
- CorMedix Expects Acquired Heron Assets to Generate About $125M-$150M of Estimated Pro Forma Rev in 2027 >CRMD HRTX
- CorMedix Expects Pro Forma 2026 Estimated Rev for Combined Business to Be $465M-$490M >CRMD, HRTX
- Heron to Get 5% Royalty on Portion of Combined Annual Net Sales of CINVANTI, SUSTOL, Products Covered by Heron's Multi-Pdt Development and License Agreement Exceeding $25M in 2027, 2028, 2029 >CRMD
- Randoncorp majority shareholder increases holdings by R$ 83,881.41
- Tonix Pharmaceuticals Q3 2026 net loss available to common stockholders widens 67% year over year to $53.3 million
- Cullinan's Velinotamig Reduces Disease Activity in 8 of 9 Evaluable Patients in Early Lupus Study
- METTLER-TOLEDO INTERNATIONAL INC. <MTD.N>: STIFEL RAISES TARGET PRICE TO $1900 FROM $1600
- Heron To Remain Publicly Traded Co With Credit Facility Repaid, Significant Position in CorMedix Common Stk, Rights to Earn-Out and Royalty Payments >CRMD
- CorMedix, Heron: Transaction's Stock Consideration Has Value of About $77.6M >CRMD
- Tonix Pharmaceuticals 3Q Loss/Shr $2.89 >TNXP
- Orthofix Medical 3Q Loss/Shr 15c >OFIX
- --B. Riley Adjusts Agenus Price Target to $16 From $14, Maintains Buy Rating
- --Earnings Flash (IBRX) ImmunityBio Posts Q3 Net Loss $0.18 a Share, vs. FactSet Est of $0.07 Loss
- --GUIDANCE: (UNIT) Uniti Expects 2026 Revenue Range $3.67B - $3.70B, vs. FactSet Est of $3.66B
- --Earnings Flash (UNIT) Uniti Group Posts Q3 Loss of $1.03 a Share, vs. FactSet Est of $0.62 Loss
- -- Earnings Flash (UNIT) Uniti Group Inc. Reports Q3 Revenue $848.1M, vs. FactSet Est of $854.4M
- -- Earnings Flash (TPB) Turning Point Brands, Inc. Posts Q3 Adjusted EPS $0.41 per Share, vs. FactSet Est of $0.35
- -- Earnings Flash (TPB) Turning Point Brands, Inc. Reports Q3 Revenue $151.1M, vs. FactSet Est of $146.7M
- Tango Therapeutics Swings to Q3 Net Loss
- Immunovant Fiscal Q2 Net Loss Narrows
- -- Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q3 Revenue $48.8M, vs. FactSet Est of $59.2M
- KKR Q3 Adjusted Net Income Rises, Revenues Decline
- International Petroleum Buys Back 158,992 Common Shares
- Affiliated Managers Group Q3 Economic Earnings, Revenue Rise
- Beyond Oil Launches CA$20 Million Private Placement
- Target Hospitality's Q3 Net Loss Widens, Revenue Rises; Lifts 2026 Revenue Guidance
- Ionis Pharmaceuticals' Q3 Net Loss Narrows as Revenue Increases; 2026 Revenue Guidance Maintained
- --Baird Initiates Amaero at Outperform With $9 Price Target
- --Guggenheim Initiates Mentari Therapeutics at Buy With $42 Price Target
- --Citigroup Initiates Iambic Therapeutics at Buy With $22 Price Target
- --JPMorgan Initiates Iambic Therapeutics at Overweight With $22 Price Target
